Through miniaturized, long-term biopharmaceutical implants, we seek to free patients from medication adherence challenges, minimizing the burden and maximizing the benefit of clinical treatments.
An alarming percentage of patients suffering from chronic illnesses don’t take their medications as prescribed, often due to the inconveniences associated with drug administration and/or tolerability, which may be associated with fluctuating drug levels.
NPM-119 is a miniature, subdermal, exenatide drug implant designed to treat the growing number of patients with type 2 diabetes. This device can be conveniently inserted under the skin during a quick outpatient procedure and is designed to provide steady doses of medication for up to six months.
We are currently preparing to initiate LIBERATE-1™, a Phase 2, First-in-Human clinical study of NPM-119 in patients with type 2 diabetes for a 12-week treatment period.